SHU-9119 SHU9119 CAS: 168482-23-3

CAS NO: 168482-23-3
SHU-9119 SHU9119
Description Review
Description
SHU-9119, with the CAS number 168482-23-3, is a compound that has garnered attention in the scientific community for its potential applications and effects. This article aims to provide a comprehensive overview of SHU-9119, delving into its chemical properties, potential benefits, mechanism of action, safety profile, and more.
Introduction:
SHU-9119 is a molecule that interacts with melanocortin receptors, specifically showing antagonist activity towards MC3 and MC4 receptors and partial agonist activity towards the MC5 receptor. Its potential applications in various fields of research make it a molecule of interest.

Chemical Name: SHU-9119
CAS Number:*168482-23-3

Top Ten Keywords from Google and Synonyms:
1. Melanocortin MC3 and MC4 receptor antagonist
2. MC5 partial agonist
3. IC50 values
4. Triglyceride synthesis
5. Lipogenesis
6. Insulin
7. Melanocortin receptor 1 (MC1R) agonist
8. MC4R antagonist
9. Human melanocortin 3 and 4 receptors (MC3/4R) antagonist
10. Synthetic

Similar Competitive Products:
While SHU-9119 is unique in its structure and activity, there may be other molecules that interact with melanocortin receptors. However, the specific competitive products would require further research and comparison based on their efficacy, safety, and mechanism of action.

Health Benefits of SHU-9119:
SHU-9119's interaction with melanocortin receptors suggests potential health benefits, including modulation of metabolic processes, such as lipogenesis and triglyceride synthesis. Its effects on insulin and other metabolic pathways could have implications in conditions like obesity and diabetes.


Potential Effects:
The potential effects of SHU-9119 are primarily related to its interaction with melanocortin receptors. It may influence metabolic processes, appetite regulation, and other physiological pathways.

Product Mechanism:
SHU-9119 acts as an antagonist to MC3 and MC4 melanocortin receptors and a partial agonist to the MC5 receptor. This means it can block the activity of MC3 and MC4 receptors while partially activating the MC5 receptor.

Safety:
Like any compound, the safety of SHU-9119 would depend on its dosage, duration of use, and individual factors. Preliminary studies suggest a favorable safety profile, but comprehensive clinical trials are essential to determine its safety in humans.

Side Effects:
The side effects of SHU-9119 are not well-documented. However, any compound that modulates physiological processes can have potential side effects. It's crucial to monitor and report any adverse reactions when using SHU-9119.

Dosing Information:
Specific dosing information for SHU-9119 would depend on its intended use, the population being studied, and other factors. It's essential to consult with experts and refer to scientific literature for appropriate dosing guidelines.

Contraindication:
There might be specific conditions or situations where the use of SHU-9119 is not recommended. Detailed studies are required to identify any contraindications.

Conclusion:
SHU-9119 is a promising molecule with potential applications in various fields of research. Its interaction with melanocortin receptors suggests potential benefits in metabolic processes and other physiological pathways. However, like any compound, it's crucial to approach its use with caution, considering its safety profile, potential side effects, and contraindications. Further research and clinical trials are essential to fully understand the potential and limitations of SHU-9119.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code